echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Xinjiang’s “2+4” Drug Purchasing Alliance Came to Promote Inter-provincial Centralized Procurement

    Xinjiang’s “2+4” Drug Purchasing Alliance Came to Promote Inter-provincial Centralized Procurement

    • Last Update: 2021-04-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
      The pace is accelerating, and another inter-provincial alliance brings a lot of purchases
     
      Xinjiang "2+4 " alliance is here
     
      On April 12, the Xinjiang Medical Insurance Bureau issued an announcement on publicly soliciting opinions and suggestions on the "2+4" Alliance of Xinjiang Production and Construction Corps of Xinjiang Uygur Autonomous Region to organize centralized drug procurement and use of drugs (draft for comments).
     
      Initiated by the Xinjiang Uygur Autonomous Region and the Xinjiang Production and Construction Corps, the alliance (the "2+4" alliance) formed by the medical institutions in Shaanxi, Gansu, Qinghai, Ningxia and other provinces and regions officially unveiled, institutionalizing the normalization of the centralized procurement of drugs .
     
      It is worth noting that this centralized procurement requires all public medical institutions and military medical institutions in the alliance area and designated chronic disease retail pharmacies in Xinjiang and Construction Corps to purchase chronic disease drugs to participate in the centralized procurement alliance.
    Encourage medical insurance designated social medical institutions and other medical insurance designated retail pharmacies to actively participate.
     
      The document shows that the scope of this purchase of drugs is drugs that are not included in the centralized drug procurement scope of the national organization, and priority is given to the types of drugs in the basic medical insurance drug catalog that have large amounts, high purchase amounts, sufficient competition, and mature clinical use.
    According to the purchase list circulated in the industry before, ten are all commonly used varieties with large clinical consumption.
     
      Purchasing drugs is divided into two quality levels according to relevant qualifications.
    The first quality level: original research drugs and reference preparations, over-evaluated generic drugs, generic drugs approved according to the new registration classification of chemical drugs, drugs included in the "China Listed Drug Catalogue", and have obtained CGMP, MHRA, FDA, JGMP certification and Export domestically produced medicines corresponding to the market.
    The second quality level: drugs other than the first quality level.
     
      In terms of price, the price declared by the enterprise should include taxes, fees, and distribution fees.
    The enterprise must comprehensively consider the distribution cost and other objective factors when quoting to ensure the supply of medicines.
    The declared price of drugs that have been purchased in other provinces, cities, or alliance provinces in a centralized manner shall not be higher than the average price of the selected prices, and the declared prices of drugs that have not been purchased in a centralized manner shall not be higher than the minimum purchase price being implemented by the national provincial procurement platform .
     
      In terms of shortlisting rules, the maximum number of shortlisted companies of the same product and quality level is determined by the actual number of companies that meet the "Quality for Variety Declaration", and the declared prices of companies that meet the price declaration requirements are determined according to the "comparable unit price" from low to high.
    , The lowest "comparable unit price" is the first rank, the second lowest is the second rank, and the other ranks are determined by analogy.
    The rules for the number of shortlisted companies are shown in the figure below.
     
      
      (Photo source: official website of Xinjiang Medical Institutions Drug Purchasing Platform)
     
      The procurement cycle of selected drugs is in principle one year.
    If the agreed procurement volume is completed in advance during the procurement cycle, the excess part will still be supplied at the selected price until the expiration of the procurement cycle.
    During the procurement cycle, if the national organization organizes a centralized drug purchase product catalog to be the same, it will be adjusted accordingly in accordance with the national policy requirements.
     
      Inter-provincial centralized procurement continues to advance
     
      In fact, the pace of centralized drug procurement in 2021 has been significantly accelerated, and several inter-provincial alliances have successively carried out mass procurement.
     
      In January 2021, the Medical Security Bureau of Sichuan and other eight provinces and autonomous regions issued a notice on the release of the "Six Provinces and Two Regions" Inter-Provincial Alliance Drug Centralized Procurement Documents.
    This inter-provincial alliance involves Sichuan Province, Shanxi Province, Inner Mongolia Autonomous Region, Liaoning Province, Jilin Province, Heilongjiang Province, Hainan Province, and Tibet Autonomous Region.
     
      In March 2021, Guangdong Pharmaceutical Trading Center issued a notice on soliciting opinions on the "Cefalexin Drug Alliance Regional Group Procurement Documents (Draft for Comment)".
    The alliance regions participating in the reporting include Guangdong, Ningxia, Henan, Qinghai, Xinjiang, Xinjiang Corps, Yunnan, Guangxi, Guizhou, and Jiangxi; Hainan does not report the volume but implements the results of the selection (not selected for online purchases).
     
      In April 2021, the Beijing-Tianjin-Hebei Pharmaceutical Joint Procurement Platform released the "Beijing-Tianjin-Hebei "3+N" Alliance Drug Joint Procurement Project Procurement Documents".
    The procurement alliance is composed of public and military medical institutions in Beijing, Tianjin, Hebei Province, and Shanxi Province, as well as designated social medical institutions with voluntary participation in medical insurance.
     
      According to the analysis, there are currently 5 inter-provincial alliances for centralized drug procurement.
    In addition to the aforementioned Sichuan 8-provincial alliance, Guangdong 11-provincial alliance, and Beijing-Tianjin-Hebei “3+N” alliance, there are also 11-provincial alliances led by Shaanxi in 2020.
    The five-province alliance led by Chongqing, in addition, the Yangtze River Delta alliance is also in the making.
     
      In general, the effect of drug price reduction under the volume procurement model of the inter-provincial alliance is obvious.
     
      A few days ago, the Beijing-Tianjin-Hebei "3+N" alliance carried out the linkage procurement of coronary dilatation balloon medical consumables, and 72 products from 31 companies were selected.
    The average product price dropped from 3,401 yuan to 319 yuan, an average decrease of 90.
    62 yuan.
    %; The "six provinces and two districts" alliance carried out centralized and volume procurement, and the
    average price of 11 selected
    drugs dropped by 58.
    05%, with the largest decrease of 91.
    69%.
     
      Judging from the participation of various provinces in the alliance, Xinjiang, Qinghai, Shanxi and other places have participated in multiple alliances at the same time.
    According to industry insiders, the basic reason for participating in the form of alliances with volume procurement is based on the problem of volume.
    The alliance has a large scope of procurement with volume, a strong bargaining chip, and a higher success rate of joint exchange for price, which may become the main direction in the future.
     
      In fact, this is also a form of procurement that has been affirmed by the upper management.
     
      From March 22 to 23, Hu Jinglin, Secretary of the Party Leadership Group and Director of the National Medical Security Administration, went to Shaanxi for research, focusing on the implementation of centralized procurement of pharmaceuticals and medical consumables organized by the state, and the development of cross-provincial alliance procurement led by Shaanxi Province.
    It is emphasized that we must unswervingly promote the reform of centralized procurement of drugs and consumables, play the leading role of regional alliances, optimize and improve working mechanisms, continue to expand the scope of centralized procurement, and implement the results of centralized procurement.
     
      With the continuous deepening of volume procurement, inter-provincial centralized procurement of more varieties will continue, and the degree of impact on enterprises will also deepen.
    Price reduction is an
    inevitable result for all
    pharmaceutical companies .
      The pace is accelerating, and another inter-provincial alliance brings a lot of purchases
     
      Xinjiang "2+4 " alliance is here
     
      On April 12, the Xinjiang Medical Insurance Bureau issued an announcement on publicly soliciting opinions and suggestions on the "2+4" Alliance of Xinjiang Production and Construction Corps of Xinjiang Uygur Autonomous Region to organize centralized drug procurement and use of drugs (draft for comments).
     
      Initiated by the Xinjiang Uygur Autonomous Region and the Xinjiang Production and Construction Corps, the alliance (the "2+4" alliance) formed by the medical institutions in Shaanxi, Gansu, Qinghai, Ningxia and other provinces and regions officially unveiled, institutionalizing the normalization of the centralized procurement of drugs .
     
      It is worth noting that this centralized procurement requires all public medical institutions and military medical institutions in the alliance area and designated chronic disease retail pharmacies in Xinjiang and Construction Corps to purchase chronic disease drugs to participate in the centralized procurement alliance.
    Encourage medical insurance designated social medical institutions and other medical insurance designated retail pharmacies to actively participate.
     
      The document shows that the scope of this purchase of drugs is drugs that are not included in the centralized drug procurement scope of the national organization, and priority is given to the types of drugs in the basic medical insurance drug catalog that have large amounts, high purchase amounts, sufficient competition, and mature clinical use.
    According to the purchase list circulated in the industry before, ten are all commonly used varieties with large clinical consumption.
     
      Purchasing drugs is divided into two quality levels according to relevant qualifications.
    The first quality level: original research drugs and reference preparations, over-evaluated generic drugs, generic drugs approved according to the new registration classification of chemical drugs, drugs included in the "China Listed Drug Catalogue", and have obtained CGMP, MHRA, FDA, JGMP certification and Export domestically produced medicines corresponding to the market.
    The second quality level: drugs other than the first quality level.
     
      In terms of price, the price declared by the enterprise should include taxes, fees, and distribution fees.
    The enterprise must comprehensively consider the distribution cost and other objective factors when quoting to ensure the supply of medicines.
    The declared price of drugs that have been purchased in other provinces, cities, or alliance provinces in a centralized manner shall not be higher than the average price of the selected prices, and the declared prices of drugs that have not been purchased in a centralized manner shall not be higher than the minimum purchase price being implemented by the national provincial procurement platform .
     
      In terms of shortlisting rules, the maximum number of shortlisted companies of the same product and quality level is determined by the actual number of companies that meet the "Quality for Variety Declaration", and the declared prices of companies that meet the price declaration requirements are determined according to the "comparable unit price" from low to high.
    , The lowest "comparable unit price" is the first rank, the second lowest is the second rank, and the other ranks are determined by analogy.
    The rules for the number of shortlisted companies are shown in the figure below.
     
      
      (Photo source: official website of Xinjiang Medical Institutions Drug Purchasing Platform)
     
      The procurement cycle of selected drugs is in principle one year.
    If the agreed procurement volume is completed in advance during the procurement cycle, the excess part will still be supplied at the selected price until the expiration of the procurement cycle.
    During the procurement cycle, if the national organization organizes a centralized drug purchase product catalog to be the same, it will be adjusted accordingly in accordance with the national policy requirements.
     
      Inter-provincial centralized procurement continues to advance
     
      In fact, the pace of centralized drug procurement in 2021 has been significantly accelerated, and several inter-provincial alliances have successively carried out mass procurement.
     
      In January 2021, the Medical Security Bureau of Sichuan and other eight provinces and autonomous regions issued a notice on the release of the "Six Provinces and Two Regions" Inter-Provincial Alliance Drug Centralized Procurement Documents.
    This inter-provincial alliance involves Sichuan Province, Shanxi Province, Inner Mongolia Autonomous Region, Liaoning Province, Jilin Province, Heilongjiang Province, Hainan Province, and Tibet Autonomous Region.
     
      In March 2021, Guangdong Pharmaceutical Trading Center issued a notice on soliciting opinions on the "Cefalexin Drug Alliance Regional Group Procurement Documents (Draft for Comment)".
    The alliance regions participating in the reporting include Guangdong, Ningxia, Henan, Qinghai, Xinjiang, Xinjiang Corps, Yunnan, Guangxi, Guizhou, and Jiangxi; Hainan does not report the volume but implements the results of the selection (not selected for online purchases).
     
      In April 2021, the Beijing-Tianjin-Hebei Pharmaceutical Joint Procurement Platform released the "Beijing-Tianjin-Hebei "3+N" Alliance Drug Joint Procurement Project Procurement Documents".
    The procurement alliance is composed of public and military medical institutions in Beijing, Tianjin, Hebei Province, and Shanxi Province, as well as designated social medical institutions with voluntary participation in medical insurance.
     
      According to the analysis, there are currently 5 inter-provincial alliances for centralized drug procurement.
    In addition to the aforementioned Sichuan 8-provincial alliance, Guangdong 11-provincial alliance, and Beijing-Tianjin-Hebei “3+N” alliance, there are also 11-provincial alliances led by Shaanxi in 2020.
    The five-province alliance led by Chongqing, in addition, the Yangtze River Delta alliance is also in the making.
     
      In general, the effect of drug price reduction under the volume procurement model of the inter-provincial alliance is obvious.
     
      A few days ago, the Beijing-Tianjin-Hebei "3+N" alliance carried out the linkage procurement of coronary dilatation balloon medical consumables, and 72 products from 31 companies were selected.
    The average product price dropped from 3,401 yuan to 319 yuan, an average decrease of 90.
    62 yuan.
    %; The "six provinces and two districts" alliance carried out centralized and volume procurement, and the
    average price of 11 selected
    drugs dropped by 58.
    05%, with the largest decrease of 91.
    69%.
     
      Judging from the participation of various provinces in the alliance, Xinjiang, Qinghai, Shanxi and other places have participated in multiple alliances at the same time.
    According to industry insiders, the basic reason for participating in the form of alliances with volume procurement is based on the problem of volume.
    The alliance has a large scope of procurement with volume, a strong bargaining chip, and a higher success rate of joint exchange for price, which may become the main direction in the future.
     
      In fact, this is also a form of procurement that has been affirmed by the upper management.
     
      From March 22 to 23, Hu Jinglin, Secretary of the Party Leadership Group and Director of the National Medical Security Administration, went to Shaanxi for research, focusing on the implementation of centralized procurement of pharmaceuticals and medical consumables organized by the state, and the development of cross-provincial alliance procurement led by Shaanxi Province.
    It is emphasized that we must unswervingly promote the reform of centralized procurement of drugs and consumables, play the leading role of regional alliances, optimize and improve working mechanisms, continue to expand the scope of centralized procurement, and implement the results of centralized procurement.
     
      With the continuous deepening of volume procurement, inter-provincial centralized procurement of more varieties will continue, and the degree of impact on enterprises will also deepen.
    Price reduction is an
    inevitable result for all
    pharmaceutical companies .
      The pace is accelerating, and another inter-provincial alliance brings a lot of purchases
     
      Xinjiang "2+4 " alliance is here
      Xinjiang "2+4 " alliance is here
     
      On April 12, the Xinjiang Medical Insurance Bureau issued an announcement on publicly soliciting opinions and suggestions on the "2+4" Alliance of Xinjiang Production and Construction Corps of Xinjiang Uygur Autonomous Region to organize centralized drug procurement and use of drugs (draft for comments).
     
      Initiated by the Xinjiang Uygur Autonomous Region and the Xinjiang Production and Construction Corps, the alliance (the "2+4" alliance) formed by the medical institutions in Shaanxi, Gansu, Qinghai, Ningxia and other provinces and regions officially unveiled, institutionalizing the normalization of the centralized procurement of drugs .
     
      It is worth noting that this centralized procurement requires all public medical institutions and military medical institutions in the alliance area and designated chronic disease retail pharmacies in Xinjiang and Construction Corps to purchase chronic disease drugs to participate in the centralized procurement alliance.
    Encourage medical insurance designated social medical institutions and other medical insurance designated retail pharmacies to actively participate.
    Pharmacy purchase pharmacy pharmacy purchase purchase
     
      The document shows that the scope of this purchase of drugs is drugs that are not included in the centralized drug procurement scope of the national organization, and priority is given to the types of drugs in the basic medical insurance drug catalog that have large amounts, high purchase amounts, sufficient competition, and mature clinical use.
    According to the purchase list circulated in the industry before, ten are all commonly used varieties with large clinical consumption.
     
      Purchasing drugs is divided into two quality levels according to relevant qualifications.
    The first quality level: original research drugs and reference preparations, over-evaluated generic drugs, generic drugs approved according to the new registration classification of chemical drugs, drugs included in the "China Listed Drug Catalogue", and have obtained CGMP, MHRA, FDA, JGMP certification and Export domestically produced medicines corresponding to the market.
    The second quality level: drugs other than the first quality level.
     
      In terms of price, the price declared by the enterprise should include taxes, fees, and distribution fees.
    The enterprise must comprehensively consider the distribution cost and other objective factors when quoting to ensure the supply of medicines.
    The declared price of drugs that have been purchased in other provinces, cities, or alliance provinces in a centralized manner shall not be higher than the average price of the selected prices, and the declared prices of drugs that have not been purchased in a centralized manner shall not be higher than the minimum purchase price being implemented by the national provincial procurement platform .
     
      In terms of shortlisting rules, the maximum number of shortlisted companies of the same product and quality level is determined by the actual number of companies that meet the "Quality for Variety Declaration", and the declared prices of companies that meet the price declaration requirements are determined according to the "comparable unit price" from low to high.
    , The lowest "comparable unit price" is the first rank, the second lowest is the second rank, and the other ranks are determined by analogy.
    The rules for the number of shortlisted companies are shown in the figure below.
     
      
      (Photo source: official website of Xinjiang Medical Institutions Drug Purchasing Platform)
     
      The procurement cycle of selected drugs is in principle one year.
    If the agreed procurement volume is completed in advance during the procurement cycle, the excess part will still be supplied at the selected price until the expiration of the procurement cycle.
    During the procurement cycle, if the national organization organizes a centralized drug purchase product catalog to be the same, it will be adjusted accordingly in accordance with the national policy requirements.
     
      Inter-provincial centralized procurement continues to advance
      Inter-provincial centralized procurement continues to advance
     
      In fact, the pace of centralized drug procurement in 2021 has been significantly accelerated, and several inter-provincial alliances have successively carried out mass procurement.
     
      In January 2021, the Medical Security Bureau of Sichuan and other eight provinces and autonomous regions issued a notice on the release of the "Six Provinces and Two Regions" Inter-Provincial Alliance Drug Centralized Procurement Documents.
    This inter-provincial alliance involves Sichuan Province, Shanxi Province, Inner Mongolia Autonomous Region, Liaoning Province, Jilin Province, Heilongjiang Province, Hainan Province, and Tibet Autonomous Region.
     
      In March 2021, Guangdong Pharmaceutical Trading Center issued a notice on soliciting opinions on the "Cefalexin Drug Alliance Regional Group Procurement Documents (Draft for Comment)".
    The alliance regions participating in the reporting include Guangdong, Ningxia, Henan, Qinghai, Xinjiang, Xinjiang Corps, Yunnan, Guangxi, Guizhou, and Jiangxi; Hainan does not report the volume but implements the results of the selection (not selected for online purchases).
     
      In April 2021, the Beijing-Tianjin-Hebei Pharmaceutical Joint Procurement Platform released the "Beijing-Tianjin-Hebei "3+N" Alliance Drug Joint Procurement Project Procurement Documents".
    The procurement alliance is composed of public and military medical institutions in Beijing, Tianjin, Hebei Province, and Shanxi Province, as well as designated social medical institutions with voluntary participation in medical insurance.
     
      According to the analysis, there are currently 5 inter-provincial alliances for centralized drug procurement.
    In addition to the aforementioned Sichuan 8-provincial alliance, Guangdong 11-provincial alliance, and Beijing-Tianjin-Hebei “3+N” alliance, there are also 11-provincial alliances led by Shaanxi in 2020.
    The five-province alliance led by Chongqing, in addition, the Yangtze River Delta alliance is also in the making.
     
      In general, the effect of drug price reduction under the volume procurement model of the inter-provincial alliance is obvious.
     
      A few days ago, the Beijing-Tianjin-Hebei "3+N" alliance carried out the linkage procurement of coronary dilatation balloon medical consumables, and 72 products from 31 companies were selected.
    The average product price dropped from 3,401 yuan to 319 yuan, an average decrease of 90.
    62 yuan.
    %; The "six provinces and two districts" alliance carried out centralized and volume procurement, and the
    average price of 11 selected
    drugs dropped by 58.
    05%, with the largest decrease of 91.
    69%.
    Medicine, medicine, medicine
     
      Judging from the participation of various provinces in the alliance, Xinjiang, Qinghai, Shanxi and other places have participated in multiple alliances at the same time.
    According to industry insiders, the basic reason for participating in the form of alliances with volume procurement is based on the problem of volume.
    The alliance has a large scope of procurement with volume, a strong bargaining chip, and a higher success rate of joint exchange for price, which may become the main direction in the future.
     
      In fact, this is also a form of procurement that has been affirmed by the upper management.
     
      From March 22 to 23, Hu Jinglin, Secretary of the Party Leadership Group and Director of the National Medical Security Administration, went to Shaanxi for research, focusing on the implementation of centralized procurement of pharmaceuticals and medical consumables organized by the state, and the development of cross-provincial alliance procurement led by Shaanxi Province.
    It is emphasized that we must unswervingly promote the reform of centralized procurement of drugs and consumables, play the leading role of regional alliances, optimize and improve working mechanisms, continue to expand the scope of centralized procurement, and implement the results of centralized procurement.
     
      With the continuous deepening of volume procurement, inter-provincial centralized procurement of more varieties will continue, and the degree of impact on enterprises will also deepen.
    Price reduction is an
    inevitable result for all
    pharmaceutical companies .
    Pharmaceutical companies Pharmaceutical pharmaceutical business enterprises
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.